[11C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer

IntroductionTo evaluate [11C]Choline positron emission tomography (PET)/computed tomography (CT) for staging and restaging of patients with advanced prostate cancer and to compare the diagnostic performance of PET, CT and PET/CT.MethodsForty-five consecutive patients with advanced prostate cancer underwent [11C]Choline-PET/CT between 5/2004 and 2/2006.ResultsOverall, 295 lesions were detected: PET alone, 178 lesions; diagnostic CT, 221 lesions; PET/CT (low-dose CT), 272 lesions; PET/CT (diagnostic CT), 295 lesions. Two thirds of the lesions were located in the bone; one third in the prostate, lymph nodes, periprostatic tissue and soft tissue (lung, liver). The use of diagnostic CT did not result in a statistically significant difference with respect to lesion localization certainty and lesion characterization (P=.063, P=.063). PET-negative but PET/CT-positive lesions were mostly localized in the bone (78%, 91/117) as were PET-positive and CT-negative lesions (72%, 53/74). Of the latter, 91% (48/53) represented bone marrow and 9% (5/53) cortical involvement.ConclusionsStaging and restaging with [11C]Choline PET/CT in patients with advanced prostate cancer improve the assessment of local and regional recurrent as well as metastatic disease including skeletal manifestations. [11C]Choline PET/CT (with a low-dose CT) results in improved localization and lesion characterization. [11C]Choline PET/CT provides an added value for skeletal manifestations. [11C]Choline PET/CT changed disease management in 11 (24%) of 45 patients with advanced prostate cancer.